Ultimate magazine theme for WordPress.
BTC
$55,007.52
-3.06%
ETH
$4,345.17
-3.08%
LTC
$194.24
-6.26%
DASH
$172.42
-2.25%
XMR
$229.23
-5%
NXT
$0.01
-3.06%
ETC
$45.81
-3.62%
DOGE
$0.20
-3.21%
ZEC
$220.21
-1.63%
BTS
$0.06
+13.04%
DGB
$0.05
+1.49%
XRP
$0.94
-3.78%
BTCD
$138.18
-3.06%
PPC
$0.85
-3.19%
CRAIG
$0.01
-3.06%
XBS
$2.63
0%
XPY
$0.01
0%
PRC
$0.00
0%
YBC
$1,800.98
0%
DANK
$0.01
-3.06%

VIEW DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages View, Inc. f/k/a CF Finance Acquisition Corp. II Investors with Losses in Excess of $100K to Secure Counsel Before Important October 18 Deadline in Securities Class Action – VIEW, CFII

NEW YORK–(BUSINESS WIRE)–WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of the securities of View, Inc. (NASDAQ: VIEW) f/k/a CF Finance Acquisition Corp. II (NASDAQ: CFII) between November 30, 2020 and August 16, 2021 (the “Class Period”), of the key deadline of October 18, 2021 as lead claimant.

SO WHAT: If you purchased View securities during the Class Period, you may be entitled to compensation without payment of cash or fees through a Contingency Compensation Scheme.

WHAT TO DO NOW: To participate in the View class action, visit http://www.roselegal.com/cases-register-2146.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for class action information. A class action lawsuit has already been filed. If you want to act as lead plaintiff, you must move the court no later than October 18, 2021. A lead plaintiff is a representative party who acts on behalf of other class members in conducting the lawsuit.

WHY ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Companies making notifications often lack comparable experience, resources, or any meaningful peer recognition. Be wise in choosing counsel. The Rosen Law Firm represents investors worldwide and focuses on securities class actions and shareholder derivative disputes. Rosen Law Firm has reached largest class action settlement ever against a Chinese firm. Rosen Law Firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company insured more than $438 million for investors. In 2020, founder Laurence Rosen was named a Titan of Eisers’ Bar by law360. Many of the firm’s attorneys are licensed by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) View had not properly incurred warranty costs with respect to its product; (2) there was a material weakness in View’s internal controls over accounting and financial reporting related to the build-up of guarantees; (3) as a result, the Company’s financial results for prior periods were incorrect; and (4) as a result, Defendants’ statements about View’s business, operations and prospects were materially inaccurate, misleading and/or lacked a reasonable basis at all relevant times. When the real details came out, the lawsuit claims investors suffered damages.

To participate in the View class action, visit http://www.roselegal.com/cases-register-2146.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for class action information.

No class is certified. Until a class is certified, you will not be represented by counsel unless you retain one. You can select an advisor of your choice. You can also remain an absent class member and do nothing at this time. An investor’s ability to participate in a possible future recovery is not dependent on acting as lead claimant.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook .com/rosenlawfirm/.

Lawyer advertising. Previous results do not guarantee a comparable outcome.

Comments are closed.